PT-141 10mg
Melanocortin peptide for sexual wellness and libido enhancement
In Stock (25 available)
SKU: ML-PT141-10MG
💰 Volume Discounts:
Buy 3+ vials = 10% off · Buy 5+ vials = 15% off
Description
PT-141 (Bremelanotide) 10mg
PT-141 is a melanocortin receptor agonist that works through the central nervous system to enhance sexual desire. Unlike PDE5 inhibitors, it acts on the brain's arousal pathways.
Key Benefits
- Acts on central arousal pathways (not vascular)
- FDA-approved version (Vyleesi) for female HSDD
- Studied in both male and female sexual dysfunction
- Works through melanocortin MC4R receptors
Research Highlights
- FDA-approved as Vyleesi for hypoactive sexual desire disorder
- Clinically studied in male erectile dysfunction
Consult with a healthcare professional for personalized guidance.
Research References
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.
Reviews treatment strategies including bremelanotide for sexual health in cancer survivors.
Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.
Systematic review of treatment options including bremelanotide for female sexual dysfunctions.
A biodegradable suction patch for sustainable transbuccal peptide delivery.
Develops a biodegradable patch for transbuccal delivery of peptides including bremelanotide.
Bremelanotide.
Comprehensive drug profile of bremelanotide's pharmacology, clinical trial results, and FDA approval for HSDD.
Novel Pharmacologic Treatments of Female Sexual Dysfunction.
Reviews novel pharmacologic treatments including bremelanotide for female sexual dysfunction.
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.
Preclinical study analyzing bremelanotide's effects on sexual behavior in female Syrian hamsters.